Podcasts about Okun

For all the doomsaying about US President Donald Trump's trade and economic policies, the world's biggest economy has held up relatively well, at least on the surface. Markets are up, trade demand remains firm and the Federal Reserve is moving toward interest rate cuts, which could spur more activity. But Steven Okun, founder and CEO of APAC Advisors, warns that the worst is yet to come. Global exports that surged in the run-up to August’s reciprocal levies are cooling, the US labor market is slowing, and markets will react once the data confirms economists’ warnings, he says. Though the slew of global levies provides some clarity, questions remain over Trump's motivations on trade policy and his tendency to upend matters with one social media post. Okun speaks with John and Katia from Singapore. Join us for Bloomberg's Investment Management Summit in Singapore on Oct. 7, featuring leading investors, asset managers and experts, to unlock insights and strategies for geopolitical volatility, technology innovation and sustainable growth. Also catch John and Katia for a live episode recording with Matthew Michelini, head of Asia-Pacific at Apollo Global Management. See you there!Register here for this exclusive event: https://events.bloombergevents.com/0BAkqmSee omnystudio.com/listener for privacy information.

In this episode #127 - of the Awakened Heart Podcast, Phyllis Okun shares her extraordinary journey of reinvention, resilience, and spiritual awakening. From her beginnings as a teacher to co-founding BLS Limo with her late husband and growing it into an international business, Phyllis has continually embraced new chapters of life. Following the profound loss of her husband, she discovered her natural gifts as a medium-work that has been endorsed by Thomas John, the “Seatbelt Psychic.” Beyond her spiritual work, Phyllis is also an award-winning, bestselling author with over 83 books published under the names Carole P. Roman and Brit Lunden, including The Big Book of Silly Jokes for Kids and the young adult novel Grady Whill and the Templeton Codex, which has been optioned for a screenplay. Known today as Lady Phyllis, she works as a professional medium with a steady clientele and has created courses to demystify mediumship for new generations. Together we explore her path of transformation, the role of intuition and family in her journey, the misconceptions around mediumship, and the beauty of embracing reinvention at any age with an awakened heart.TakeawaysPhyllis transitioned from teaching to entrepreneurship while maintaining her passion for writing.Her family's involvement in mediumship showcases a unique dynamic of shared spiritual abilities.Mediumship is not a gift but an ability that anyone can develop with practice.Evidential mediumship focuses on providing specific information that validates connections with the deceased.Misconceptions about mediumship often stem from a lack of understanding of its true nature.Reinvention is a vital part of life, and change should be embraced as an opportunity for growth.Phyllis's journey into mediumship began after personal loss, leading her to explore her abilities.Trusting one's intuition and spirit guides is essential in the practice of mediumship.Life is a smorgasbord of experiences, and trying new things can lead to unexpected joys.Living with an awakened heart means being of service to others and finding fulfillment in one's journey.Sound Bites"It's not a gift, it's an ability.""Life's a smorgasbord.""I feel privileged to be of service."Connect with PhyllisWebsiteInstagramYoutubeFacebookTwitterLet's Connect!⁠⁠Website⁠⁠⁠Instagram⁠ ⁠Facebook⁠⁠Youtube⁠⁠Rumble⁠⁠⁠Tik Tok⁠⁠⁠Linkedin⁠⁠Linktree⁠Keywordsmediumship, entrepreneurship, personal growth, family dynamics, teaching, spirituality, reinvention, evidential mediumship, Phyllis Okon, Awaken Heart Podcast

Multiple system atrophy is a rare, sporadic, adult-onset, progressive, and fatal neurodegenerative disease. Accurate and early diagnosis remains challenging because it presents with a variable combination of symptoms across the autonomic, extrapyramidal, cerebellar, and pyramidal systems. Advances in brain imaging, molecular biomarker research, and efforts to develop disease-modifying agents have shown promise to improve diagnosis and treatment. In this episode, Casey Albin, MD speaks with Tao Xie, MD, PhD, author of the article “Multiple System Atrophy” in the Continuum® August 2025 Movement Disorders issue. Dr. Albin is a Continuum® Audio interviewer, associate editor of media engagement, and an assistant professor of neurology and neurosurgery at Emory University School of Medicine in Atlanta, Georgia. Dr. Xie is director of the Movement Disorder Program, chief of the Neurodegenerative Disease Section in the department of neurology at the University of Chicago Medicine in Chicago, Illinois. Additional Resources Read the article: Multiple System Atrophy Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @caseyalbin Full episode transcript available here Dr. Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Albin: Hello everyone, this is Dr Casey Albin. Today I'm interviewing Dr Tao Xie about his article on diagnosis and management of multiple system atrophy, which appears in the August 2025 Continuum issue on movement disorders. Welcome to the podcast, and please introduce yourself to our audience. Dr Xie: Thank you so much, Dr Albin. My name is Tao Xie, and sometimes people also call me Tao Z. I'm a mood disorder neurologist, professor of neurology at the University of Chicago. I'm also in charge of the mood disorder program here, and I'm the section chief in the neurodegenerative disease in the Department of Neurology at the University of Chicago Medicine. Thank you for having me, Dr Albin and Dr Okun and the American Academy of Neurology. This is a great honor and pleasure to be involved in this education session. Dr Albin: We are delighted to have you, and thank you so much for the thoughtful approach to the diagnosis and management. I really want to encourage our listeners to check out this article. You know, one of the things that you emphasize is multiple system atrophy is a fairly rare condition. And I suspect that clinicians and trainees who even have a fair amount of exposure to movement disorders may not have encountered that many cases. And so, I was hoping that you could just start us off and walk us through what defines multiple system atrophy, and then maybe a little bit about how it's different from some of the more commonly encountered movement disorders. Dr Xie: This is a really good question, Dr Albin. Indeed, MSA---multisystem atrophy----is a rare disease. It is sporadic, adult-onset, progressive, fatal neurodegenerative disease. By the name MSA, multisystem atrophy. Clinically, it will present with multiple symptoms and signs involving multiple systems, including symptoms of autonomic dysfunction and symptoms of parkinsonism, which is polyresponsive to the levodopa treatment; and the symptom of cerebellar ataxia, and symptom of spasticity and other motor and nonmotor symptoms. And you may be wondering, what is the cause- underlying cause of these symptoms? Anatomically, we can find the area in the basal ganglia striatonigral system, particularly in the putamen and also in the cerebellar pontine inferior, all of the nuclear area and the specific area involved in the autonomic system in the brain stem and spinal cord: all become smaller. We call it atrophy. Because of the atrophy in this area, they are responsible for the symptom of parkinsonism if it is involved in the putamen and the cerebral ataxia, if it's involved in the pons and cerebral peduncle and the cerebellum. And all other area, if it's involved in the autonomic system can cause autonomic symptoms as well. So that's why we call it multisystem atrophy. And then what's the underlying cellular and subcellular pathological, a hallmark that is in fact caused by misfolded alpha-synuclein aggregate in the oligodontia site known as GCI---glial cytoplasmic increasing bodies---in the cells, and sometimes it can also be found in the neuronal cell as well in those areas, as mentioned, which causes the symptom. But clinically, the patient may not present all the symptoms at the same time. So, based on the predominant clinical symptom, if it's mainly levodopa, polyresponsive parkinsonism, then we call it MSAP. If it's mainly cerebellar ataxia, then we call it MSAC. But whether we call it MSP or MSC, they all got to have autonomic dysfunction. And also as the disease progresses, they can also present both phenotypes together. We call that mixed cerebellar ataxia and parkinsonism in the advanced stage of the disease. So, it is really a complicated disease. The complexity and the similarity to other mood disorders, including parkinsonism and the cerebellar ataxia, make it really difficult sometimes, particularly at the early stages of disease, to differentiate one from the other. So, that was challenging not only for other professionals, general neurologists and even for some movement disorder specialists, that could be difficult particularly if you aim to make an accurate and early diagnosis. Dr Albin: Absolutely. That is such a wealth of knowledge here. And I'm going to distill it just a little bit just to make sure that I understand this right. There is alpha-synuclein depositions, and it's really more widespread than one would see maybe in just Parkinson's disease. And with this, you are having patients present with maybe one of two subtypes of their clinical manifestations, either with a Parkinson's-predominant movement disorder pattern or a cerebellar ataxia type movement disorder pattern. Or maybe even mixed, which really, you know, we have to make things quite complicated, but they are all unified and having this shared importance of autonomic features to the diagnosis. Have I got that all sort of correct? Dr Xie: Correct. You really summarize well. Dr Albin: Fantastic. I mean, this is quite a complicated disease. I would pose to you sort of a case, and I imagine this is quite common to what you see in your clinic. And let's say, you know, a seventy-year-old woman comes to your clinic because she has had rigidity and poor balance. And she's had several falls already, almost always from ground level. And her family tells you she's quite woozy whenever she gets up from the chair and she tends to kind of fall over. But they noticed that she's been stiff,and they've actually brought her to their primary care doctor and he thought that she had Parkinson's disease. So, she started levodopa, but they're coming to you because they think that she probably needs a higher dose. It's just not working out very well for her. So how would you sort of take that history and sort of comb through some of the features that might make you more concerned that the patient actually has undiagnosed multiple systems atrophy? Dr Xie: This is a great case, because we oftentimes can encounter similar cases like this in the clinic. First of all, based on the history you described, it sounds like an atypical parkinsonism based on the slowness, rigidity, stiffness; and particularly the early onset of falls, which is very unusual for typical Parkinson disease. It occurs too early. If its loss of balance, postural instability, and fall occurred within three years of disease onset---usually the motor symptom onset---then it raises a red flag to suspect this must be some atypical Parkinson disorders, including multiple system atrophy. Particularly, pou also mentioned that the patient is poorly responsive to their levodopa therapy, which is very unusual because for Parkinson disease, idiopathic Parkinson disease, we typically expect patients would have a great response to the levodopa, particularly in the first 5 to 7 years. So to put it all together, this could be atypical parkinsonism, and I could not rule out the possibility of MSA. Then I need to check more about other symptoms including autonomic dysfunction, such as orthostatic hypertension, which is a blood pressure drop when the patient stands up from a lying-down position, or other autonomic dysfunctions such as urinary incontinence or severe urinary retention. So, in the meantime, I also have to put the other atypical Parkinson disorder on the differential diagnosis, such as PSP---progressive supranuclear palsy---and the DLBD---dementia with Lewy body disease.---Bear this in mind. So, I want to get more history and more thorough bedside assessment to rule in or rule out my diagnosis and differential diagnosis. Dr Albin: That's super helpful. So, looking for early falls, the prominence of autonomic dysfunction, and then that poor levodopa responsiveness while continuing to sort of keep a very broad differential diagnosis? Dr Xie: Correct. Dr Albin: One of the things that I just have to ask, because I so taken by this, is that you say in the article that some of these patients actually have preservation of smell. In medical school, we always learn that our Parkinson's disease patients kind of had that early loss of smell. Do you find that to be clinically relevant? Is that- does that anecdotally help? Dr Xie: This is a very interesting point because we know that the loss of smelling function is a risk effect, a prodromal effect, for the future development of Parkinson disease. But it is not the case for MSA. Strange enough, based on the literature and the studies, it is not common for the patient with MSA to present with anosmia. Some of the patients may have mild to moderate hyposmia, but not to the degree of anosmia. So, this is why even in the more recent diagnosis criteria, the MDS criteria published 2022, it even put the presence of anosmia in the exclusion criteria. So, highlight the importance of the smell function, which is well-preserved for the majority in MSA, into that category. So, this is a really interesting point and very important for us, particularly clinicians, to know the difference in the hyposmia, anosmia between the- we call it the PD, and the dementia Lewy bodies versus MSA. Dr Albin: Fascinating. And just such a cool little tidbit to take with us. So, the family, you know, you're talking to them and they say, oh yes, she has had several fainting episodes and we keep taking her to the primary care doctor because she's had urinary incontinence, and they thought maybe she had urinary tract infections. We've been dealing with that. And you're sort of thinking, hm, this is all kind of coming together, but I imagine it is still quite difficult to make this diagnosis based on history and physical alone. Walk our listeners through sort of how you're using MRI and DAT scan and maybe even some other biomarkers to help sort of solidify that diagnosis. Dr Xie: Yeah, that's a wonderful question. Yeah. First of all, UTI is very common for patients with MSA because of urinary retention, which puts them into a high risk of developing frequent UTI. That, for some patients, could be the very initial presentation of symptoms. In this case, if we check, we say UTI is not present or UTI is present but we treat it, then we check the blood pressure and we do find also hypertension---according to new diagnosis criteria, starting drop is 20mm mercury, but that's- the blood pressure drop is ten within three minutes. And also, in the meantime the patients present persistent urinary incontinence even after UTI was treated. And then the suspicion for MS is really high right at this point. But if you want increased certainty and a comfortable level on your diagnosis, then we also need to look at the brain MRI mark. This is a required according to the most recent MDS diagnosis criteria. The presence of the MRI marker typical for MSA is needed for the diagnosis of clinically established MSA, which holds the highest specificity in the clinical diagnosis. So then, we have- we're back to your question. We do need to look at the brain MRI to see whether evidence suggestive of atrophy around the putamen area, around the cerebellar pontine inferior olive area, is present or not. Dr Albin: Absolutely. That's super helpful. And I think clinicians will really take that to sort of helping to build a case and maybe recognizing some of this atypical Parkinson's disease as a different disease entity. Are there any other biomarkers in the pipeline that you're excited about that may give us even more clarity on this diagnosis? Dr Xie: Oh, yeah. This is a very exciting area. In terms of biomarker for the brain imaging, particularly brain MRI, in fact, today there's a landmark paper just published in the Java Neurology using AI, artificial intelligence or machine learning aid, diagnoses a patient with parkinsonism including Parkinson's disease, MSA, and PSP, with very high diagnostic accuracy ranging from 96% to 98%. And some of the cases even were standard for autopsy, with pathological verification at a very high accurate rate of 93.9%. This is quite amazing and can really open new diagnosis tools for us to diagnose this difficult disease; not only in an area with a bunch of mood disorder experts, but also in the rural area, in the area really in need of mood disorder experts. They can provide tremendous help to provide accurate, early diagnosis. Dr Albin: That's fantastic and I love that, increasing the access to this accurate diagnosis. What can't artificial intelligence do for us? That's just incredible. Dr Xie: And also, you know, this is just one example of how the brain biomarker can help us. Theres other---a fluid biomarker, molecular diagnostic tools, is also available. Just to give you an example, one thing we know over the past couple years is skin biopsy. Through the immunofluorescent reaction, we can detect whether the hallmark of abnormally folded, misfolded, and the phosphorate, the alpha-synuclein aggregate can be found just by this little pinch of skin biopsy. Even more advanced, there's another diagnosis tool we call the SAA, we call the seizure amplification assay, that can even help us to differentiate MSA from other alpha-synucleinopathy, including Parkinson disease and dementia with Lewy bodies. If we get a little sample from CSF, spinal cerebral fluids, even though this is probably still at the early stage, a lot of developments still ongoing, but this, this really shows you how exciting this area is now. We're really in a fast forward-moving path now. Dr Albin: It's really incredible. So, lots coming down the track in, sort of, MRI, but also with CSF diagnosis and skin biopsies. Really hoping that we can hone in some of those tools as they become more and more validated to make this diagnosis. Is that right? Dr Xie: Correct. Dr Albin: Amazing. We can talk all day about how you manage these in the clinic, and I really am going to direct our listeners to go and read your fantastic article, because you do such an elegant job talking about how this takes place in a multidisciplinary setting, if at all possible. But as a neurointensivist, I was telling you, we have so much trouble in the hospital. We have A-lines, and we have the ability to get rapid KUBs to look at Ilias, and we can have many people as lots of diagnosis, and we still have a lot of trouble treating autonomiclike symptoms. Really, really difficult. And so, I just wanted to kind of pick your brain, and I'll start with just the one of orthostatic hypotension. What are some of the tips that you have for, you know, clinicians that are dealing with this? Because I imagine that this is quite difficult to do without patients. Dr Xie: Exactly. This is indeed a very difficult symptom to deal with, particularly at an outpatient setting. But nowadays with the availability of more medication---to give an example, to treat patients with orthostatic hypertension, we have not only midodrine for the cortisol, we also have droxidopa and several others as well. And so, we have more tools at hand to treat the patient with orthostatic hypertension. But I think the key thing here, particularly for us to the patient at the outpatient setting: we need to educate the patient's family well about the natural history of the disease course. And we also need to tell them what's the indication and the potential side effect profile of any medication we prescribe to them so that they can understand what to expect and what to watch for. And in the meantime, we also need to keep really effective and timely communication channels, make sure that the treating physician and our team can be reached at any time when the patient and family need us so that we can be closely monitoring, their response, and also monitoring potential side effects as well to keep up the quality of care in that way. Dr Albin: Yeah, I imagine that that open communication plays a huge role in just making sure that patients are adapting to their symptoms, understanding that they can reach out if they have refractory symptoms, and that- I imagine this takes a lot of fine tuning over time. Dr Xie: Correct. Dr Albin: Well, this has just been such a delight to get to talk to you. I really feel like we could dive even deeper, but I know for the sake of time we have to kind of close out. Are there any final points that you wanted to share with our listeners before we end the interview? Dr Xie: I think for the patients, I want them to know that nowadays with advances in science and technology, particularly given a sample of rapid development in the diagnostic tools and the multidisciplinary and multisystemic approach to treatment, nowadays we can make an early and accurate diagnosis of the MSA, and also, we can provide better treatment. Even though so far it is still symptomatically, mainly, but in the near future we hope we can also discover disease-modifying treatment which can slow down, even pause or prevent the disease from happening. And for the treating physician and care team professionals, I just want them to know that you can make a difference and greatly help the patient and the family through your dedicated care and also through your active learning and innovative research. You can make a difference. Dr Albin: That's amazing and lots of hope for these patients. Right now, you can provide really great care to take care of them, make an early and accurate diagnosis; but on the horizon, there are really several things that are going to move the field forward, which is just so exciting. Again today, I've been really greatly honored and privileged to be able to talk to Dr Tao Xie about his article on diagnosis and management of multiple system atrophy, which appears in the August 2025 Continuum issue on movement disorders. Be sure to check out Continuum Audio episodes for this and other issues. And thank you again to our listeners for joining us today. Dr Xie: Thank you so much for having me. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

Dr. Michael Okun, a neurologist at University of Florida, has spent almost 25 years researching Parkinson's and treating people with Parkinson's. Now, in one of the best written and most accessible books ever written on Parkinson's, Dr. Okun and Dr. Ray Dorsey lay out the plan:What causes Parkinson's?What can be done to prevent it?What do you do once you have it?Listen in as we look at the history and the rapid rise of Parkinson's to a point where it is often being considered a pandemic.For more information on The Parkinson's Plan and to purchase the book, click here: https://pdplan.org/

Parkinson's disease is rising faster than ever before — with 90,000 new U.S. cases every year. But what if it's not just bad luck, aging, or genetics? In this powerful conversation (watch HERE on YouTube), one of the world's leading neurologists, Dr. Michael Okun, reveals shocking truths from the new book The Parkinson's PLAN, co-authored with Dr. Ray Dorsey:  ☠️ The hidden toxins in our air, water, and food that are driving the disease

Trump’s tariffs kick in… shocking some long-standing trading partners. US allies go their own way to force diplomatic shift on Gaza. And… YouTube to be included in Australia's teen social media ban. During our International News Review, “Saturday Mornings Show” host Glenn van Zutphen and co-host Neil Humphreys speak to Steve Okun, CEO APAC Advisors.See omnystudio.com/listener for privacy information.

In this episode, Lyell K. Jones Jr, MD, FAAN, speaks with Michael S. Okun, MD, FAAN, who served as the guest editor of the August 2025 Movement Disorders issue. They provide a preview of the issue, which publishes on August 1, 2025. Dr. Jones is the editor-in-chief of Continuum: Lifelong Learning in Neurology® and is a professor of neurology at Mayo Clinic in Rochester, Minnesota. Dr. Okun is the director at Norman Fixel Institute for Neurological Diseases and distinguished professor of neurology at University of Florida in Gainesville, Florida. Additional Resources Read the issue: continuum.aan.com Subscribe to Continuum®: shop.lww.com/Continuum Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @LyellJ Guest: @MichaelOkun Full episode transcript available here: Dr Jones: Our ability to move through the world is one of the essential functions of our nervous system. Gross movements like walking ranging down to fine movements with our eyes and our hands, our ability to create and coordinate movement is something many of us take for granted. So what do we do when those movements stop working as we intend? Today I have the opportunity to speak with one of the world's leading experts on movement disorders, Dr Michael Okun, about the latest issue of Continuum on Movement Disorders. Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about subscribing to the journal, listening to verbatim recordings of the articles, and exclusive access to interviews not featured on the podcast. Dr Jones: This is Dr Lyle Jones, Editor-in-Chief of Continuum: Lifelong Learning in Neurology. Today, I'm interviewing Dr Michael Okun, who is Continuum's guest editor for our latest issue on movement disorders. Dr Okun is the Adelaide Lackner Distinguished Professor of Neurology at the University of Florida in Gainesville, where he's also the director of the Norman Fixel Institute for Neurological Diseases. Dr Okun, welcome, and thank you for joining us today. Why don't you introduce yourselves to our listeners?  Dr Okun: It's great to be here today. And I'm a neurologist. Everybody who knows me knows I'm pretty simple. I believe the patient's the sun and we should always orbit around the person with disease, and so that's how I look at my practice. And I know we always participate in a lot of research, and I've got a research lab and all those things. But to me, it's always the patients and the families first. So, it'll be great to have that discussion today.  Dr Jones: Yeah, thank you for that, Dr Oaken. Obviously, movement disorders is a huge part of our field of neurology. There are many highly prevalent conditions that fit into this category that most of our listeners will be familiar with: idiopathic Parkinson's disease, essential tremor, tic disorders and so on. And having worked with trainees for a long time, it's one of the areas that I see a lot of trainees gravitate to movement disorders. And I think it's in part because of the prevalence; I think it's in part because of the diversity of the specialty with treatment options and DBS and Botox. But it's also the centrality of the neurologic exam, right? That's- the clinical examination of the patient is so fundamental. And we'll cover a lot of topics today with some questions that I have for you about biomarkers and new developments in the field. But is that your sense too, that people are drawn to just the old-fashioned, essential focus on the neurologic encounter and the neurologic exam? Dr Okun: I believe that is one of the draws to the field of movement. I think that you have neurologists from all over the world that are really interested and fascinated with what things look like. And when you see something that's a little bit, you know, off the normal road or off the normal beaten path… and we are always curious. And so, I got into movement disorders, I think, accidentally; I think even as a child, I was looking at people who had abnormal movements and tremors and I was very fascinated as to why those things happened and what's going on in the brain. And, you know, what are the symptoms and the signs. And then later on, even as my own career developed, that black bag was so great as a neurologist. I mean, it makes us so much more powerful than any of the other clinicians---at least in my biased opinion---out on the wards and out in the clinic. And, you know, knowing the signs and the symptoms, knowing how to do a neurological examination and really walking through the phenomenology, what people look like, you know, which is different than the geno- you know, the genotypes, what the genes are. What people look like is so much more important as clinicians. And so, I think that movement disorders is just the specialty for that, at least in my opinion. Dr Jones: And it helps bring it back to the patient. And that's something that I saw coming through the articles in this issue. And let's get right to it. You've had a chance to review all these articles on all these different topics across the entire field of movement disorders. As you look at that survey of the field, Dr Okun, what do you think is the most exciting recent development for patients with movement disorders?  Dr Okun: I think that when you look across all of the different specialties, what you're seeing is a shift. And the shift is that, you know, a lot of people used to talk in our generation about neurology being one of these “diagnose and adios” specialties. You make the diagnosis and there's nothing that you can do, you know, about these diseases. And boy, that has changed. I mean, we have really blown it out of the water. And when you look at the topics and what people are writing about now and the Continuum issue, and we compare that the last several Continuum issues on movement disorders, we just keep accumulating a knowledge base about what these things look like and how we can treat them. And when we start thinking about, you know, all of the emergence of the autoimmune disorders and identifying the right one and getting something that's quite treatable. Back in my day, and in your day, Lyle, we saw these things and we didn't know what they were. And now we have antibodies, now we can identify them, we can pin them down, and we can treat many of them and really change people's lives. And so, I'm really impressed at what I see in changes in identification of autoimmune disorders, of channelopathies and some of the more rare things, but I'm also impressed with just the fundamental principles of how we're teaching people to be better clinicians in diseases like Parkinson's, Huntington's, ataxia, and Tourette. And so, my enthusiasm for this issue of Continuum is both on, you know, the cutting edge of what we're seeing based on the identification on our exams, what we can do for these people, but also the emergence of how we're shifting and providing much better care across a continuum for folks with basal ganglia diseases. Dr Jones: Yeah, I appreciate that perspective, Dr Okun. One of the common themes that I saw in the issue was with these new developments, right, when you have new tools like new diagnostic biomarker tools, is the question of if and when and how to integrate those into daily clinical practice, right? So, we've had imaging biomarkers for a while, DAT scans, etc. For patients with idiopathic Parkinson disease, one of the things that I hear a lot of discussion and controversy about are the seed amplification assays as diagnostic biomarkers. What can you tell us about those? Are those ready for routine clinical use yet?  Dr Okun: I think the main bottom-line point for folks that are out there trying to practice neurology, either in general clinics or even in specialty clinics, is to know that there is this movement toward, can we biologically classify a disease? One of the things that has, you know, really accelerated that effort has been the development of these seed amplification assays, which---in short for people who are listening---are basically, we “shake and bake” these things. You know? We shake them for like 20 hours and we use these prionlike proteins, and we learn from diseases like prion disease how to kind of tag these things and then see, do they have degenerative properties? And in the case of Parkinson's disease, we're able to do this with synuclein. That is the idea of a seed amplification assay. We're able to use this to see, hey, is there synuclein present or not in this sample? And people are looking at things like cerebrospinal fluid, they're looking at things like blood and saliva, and they're finding it. The challenge here is that, remember- and one of the things that's great about this issue of Continuum is, remember, there are a whole bunch of different synucleinopathies. So, Dr Jones, it isn't just Parkinson's disease. So, you've got Parkinson's disease, you've got Lewy body, you know, and dementia with Lewy bodies. You've got, you know, multiple system atrophy is within that synucleinopathy, you know, group primary autonomic failure… so not just Parkinson's disease. And so, I think we have to tap the brakes as clinicians and just say, we are where we are. We are moving in that direction. And remember that a seed amplification assay gives you some information, but it doesn't give you all the information. It doesn't forgive you looking at a person over time, examining them in your clinic, seeing how they progress, seeing their response to dopamine- and by the way, several of these genes that are associated with Parkinson; and there's, you know, less than 20% of Parkinson is genetic, but several of these genes, in a solid third---and in some cases, in some series, even more---miss the synuclein assay, misses, you know, the presence of a disease like Parkinson's disease. And so, we have to be careful in how we interpret it. And I think we're more likely to see over time a gemish: we're going to smush together all this information. We're going to get better with MRIs. And so, we're actually doing much better with MRIs and AI-based intelligence. We've got DAT scans, we've got synuclein assays. But more than anything, everybody listening out there, you can still examine the person and examine them over time and see how they do over time and see how they do with dopamine. And that is still a really, really solid way to do this. The synuclein assays are probably going to be ready for prime time more in choosing and enriching clinical trials populations first. And you know, we're probably 5, 10 years behind where Alzheimer's is right now. So, we'll get there at some point, but it's not going to be a silver bullet. I think we're looking at these are going to be things that are going to be interpreted in the context for a clinician of our examination and in the context of where the field is and what you're trying to use the information for. Dr Jones: Thank you for that. And I think that's the general gestalt I got from the articles and what I hear from my colleagues. And I think we've seen this in other domains of neurology, right? We have the specificity and sensitivity issues with the biomarkers, but we also have the high prevalence of copathology, right? People can have multiple different neurodegenerative problems, and I think it gets back to that clinical context, like you said, following the patient longitudinally. That was a theme that came out in the idiopathic Parkinson disease article. And while we're on Parkinson disease, you know, the first description of that was what, more than two hundred years ago. And I think we're still thinking about the pathophysiology of that disorder. We understand risk factors, and I think many of our listeners would be familiar with those. But as far as the actual cause, you know, there's been discussion in recent years about, is there a role of the gut microbiome? Is this a prionopathic disorder? What's your take on all of that?  Dr Okun: Yeah, so it's a great question. It's a super-hot area right now of Parkinson. And I kind of take this, you know, apart in a couple of different ways. First of all, when we think about Parkinson disease, we have to think upstream. Like, what are the cause and causes? Okay? So, Parkinson is not one disease, okay? And even within the genes, there's a bunch of different genes that cause it. But then we have to look and say, well, if that's less than 20% depending on who's counting, then 80% don't have a single piece of DNA that's closely associated with this syndrome. And so, what are we missing with environment and other factors? We need to understand not what happens at the end of the process, not necessarily when synuclein is clumping- and by the way, there's a lot of synuclein in the brains normally, and there's a lot of Tau in people's brains who have Parkinson as well. We don't know what we don't know, Dr Jones. And so when we begin to think about this disease, we've got to look upstream. We've got to start to think, where do things really start? Okay? We've got to stop looking at it as probably a single disease or disorder, and it's a circuit disorder. And then as we begin to develop and follow people along that pathway and continuum, we're going to realize that it's not a one-size-fits-all equation when we're trying to look at Parkinson. By the way, for people listening, we only spend two to three cents out of every dollar on prevention. Wouldn't prevention be the best cure, right? Like, if we were thinking about this disease. And so that's something that we should be, you know, thinking about. And then the other is the Global Burden of Disease study. You know, when we wrote about this in a book called Ending Parkinson's Disease, it looked like Parkinson's was going to double by 2035. The new numbers tell us it's almost double to the level that we expected in 2035 in this last series of numbers. So, it's actually growing much faster. We have to ask why? Why is it growing faster? And then we have lots of folks, and even within these issues here within Continuum, people are beginning to talk about maybe these environmental things that might be blind spots. Is it starting in our nose? Is it starting in our gut? And then we get to the gut question. And the gut question is, if we look at the microbiomes of people with Parkinson, there does seem to be, in a group of folks with Parkinson, a Parkinson microbiome. Not in everyone, but if you look at it in composite, there seems to be some clues there. We see changes in Lactobacillus, we see some bacteria going up that are good, some bacteria going down, you know, that are bad. And we see flipping around, and that can change as we put people on probiotics and we try to do fecal microbiota transplantations- which, by the way, the data so far has not been positive in Parkinson's. Doesn't mean we might not get there at some point, but I think the main point here is that as we move into the AI generation, there are just millions and millions and millions of organisms within your gut. And it's going to take more than just our eyes and just our regular arithmetic. You and I probably know how to do arithmetic really well, but this is, like, going to be a much bigger problem for computers that are way smarter than our brains to start to look and say, well, we see the bacteria is up here. That's a good bacteria, that's a good thing or it's down with this bacteria or this phage or there's a relationship or proportion that's changing. And so, we're not quite there. And so, I always tell people---and you know, we talk about the sum in the issue---microbiomes aren't quite ready for prime time yet. And so be careful, because you could tweak the system and you might actually end up worse than before you started. So, we don't know what we don't know on this issue.  Dr Jones: And that's a great point. And one of the themes they're reading between the lines is, we will continue to work on understanding the bio-pathophysiology, but we can't wait until that day to start managing the risk factors and treating patients, which I think is a good point. And if we pivot to treatment here a little bit, you know, one of the exciting areas of movement disorders---and really neurology broadly, I think movement disorders has led the field in many ways---is bioelectronic therapy, or what one of my colleagues taught me is “electroceutical therapy”, which I think is a wonderful term. Dr Okun, when our listeners are hearing about the latest in deep brain stimulation in patients who have movement disorders, what should they know? What are the latest developments in that area with devices? Dr Okun: Yeah. So, they should know that things are moving rapidly in the field of putting electricity into the brain. And we're way past the era where we thought putting a little bit of electricity was snake oil. We know we can actually drive these circuits, and we know that many of these disorders---and actually, probably all of the disorders within this issue of Continuum---are all circuit disorders. And so, you can drive the circuit by modulating the circuit. And it's turned out to be quite robust with therapies like deep brain stimulation. Now, we're seeing uses of deep brain stimulation across multiple of these disorders now. So, for example, you may think of it in Parkinson's disease, but now we're also seeing people use it to help in cases where you need to palliate very severe and bothersome chorea and Huntington's disease, we're seeing it move along in Tourette syndrome. We of course have seen this for various hyperkinetic disorders and dystonias. And so, the main thing for clinicians to realize when dealing with neuromodulation is, take a deep breath because it can be overwhelming. We have a lot of different devices in the marketplace and no matter how many different devices we have in the marketplace, the most important thing is that we get the leads. You know, where we're stimulating into the right location. It's like real estate: location, location, location, whether you've got a lead that can steer left, right, up, down and do all of these things. Second, if you're feeling overwhelmed because there are so many devices and so many settings, especially as we put these leads in and they have all sorts of different, you know, nodes on them and you can steer this way and that way, you are not alone. Everybody is feeling that way now. And we're beginning to see AI solutions to that that are going to merge together with imaging, and then we're moving toward an era of, you know, should I say things like robotic programming, where it's going to be actually so complicated as we move forward that we're going to have to automate these systems. There's no way to get this and scale this for all of the locales within the United States, but within the entire world of people that need these types of devices and these therapies. And so, it's moving rapidly. It's overwhelming. The most important thing is choosing the right person. Okay? For this, with multidisciplinary teams, getting the lead in the right place. And then all these other little bells and whistles, they're like sculpting. So, if you think of a sculpture, you kind of get that sculpture almost there. You know, those little adds are helping to maybe make the eyes come out a little more or the facial expression a little bit better. There's little bits of sculpting. But if you're feeling overwhelmed by it, everybody is. And then also remember that we're starting to move towards some trials here that are in their early stages. And a lot of times when we start, we need more failures to get to our successes. So, we're seeing trials of people looking at, like, oligo therapies and protein therapies. We're seeing CRISPR gene therapies in the laboratory. And we should have a zero tolerance for errors with CRISPR, okay? we still have issues with CRISPR in the laboratory and which ones we apply it to and with animals. But it's still pretty exciting when we're starting to see some of these therapies move forward. We're going to see gene therapies, and then the other thing we're going to see are nano-therapies. And remember, smaller can be better. It can slip across the blood brain barrier, you have very good surface area-to-volume ratios, and we can uncage drugs by shining things like focused ultrasound beams or magnets or heat onto these particles to turn them on or off. And so, we're seeing a great change in the field there. And then also, I should mention: pumps are coming and they're here. We're getting pumps like we have for diabetes and neurology. It's very exciting. It's going to be overwhelming as everybody tries to learn how to do this. So again, if you're feeling overwhelmed, so am I. Okay? But you know, pumps underneath the skin for dopamine, pumps underneath the skin for apomorphine. And that may apply to other disorders and not just Parkinson as we move along, what we put into those therapies. So, we're seeing that age come forward. And then making lesions from outside the brain with focused ultrasound, we're starting to get better at that. Precision is less coming from outside the brain; complications are also less. And as we learn how to do that better, that also can provide more options for folks. So, a lot of things to read about in this issue of Continuum and a lot of really interesting and beyond, I would say, you know, the horizon as to where we're headed.  Dr Jones: Thank you for that. And it is a lot. It can be overwhelming, which I guess is maybe a good reason to read the issue, right? I think that's a great place to end and encourage our listeners to pick up the issue. And Dr Okun, I want to thank you for joining us today. Thank you for such a great discussion on movement disorders. I learned a lot. I'm sure our listeners will as well, given the importance of the topic, your leadership in the field over many years. I'm grateful that you have put this issue together. So, thank you. And you're a busy person. I don't know how we talked you into doing this, but I'm really glad that we did.  Dr Okun: Well, it's been my honor. And I just want to point out that the whole authorship panel that agreed to write these articles, they did all the work. I'm just a talking head here, you know, telling you what they did, but they're writing, and the people that are in the field are really, you know, leading and helping us to understand, and have really put it together in a way that's kind of helped us to be better clinicians and to impact more lives. So, I want to thank the group of authors, and thank you, Dr Jones. Dr Jones: Again, we've been speaking with Dr Michael Okun, guest editor of Continuum's most recent issue on movement disorders. Please check it out. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. Thank you for listening to Continuum Audio.

During the International News Review, “Saturday Mornings Show” host Glenn van Zutphen and co-host Neil Humphreys speak to Steve Okun, CEO APAC Advisors about Israel's attack on Iran, the one survivor of Air India's crash, what's the deal with US troops on American streets, and the passing of music icons Brian Wilson and Sly Stone.See omnystudio.com/listener for privacy information.

To subscribe to our podcast and YouTube channel visit: https://www.youtube.com/@davisphinneyfdn/podcasts In this episode, we're sharing an excerpt from our May 2025 Live Well Today webinar about Emerging Therapies for Parkinson's, which features Dr. Soania Mathur and Dr. Michael Okun. In this excerpt, Dr. Mathur and Dr. Okun discuss three emerging treatments for Parkinson's that are designed for continuous under-the-skin infusion. These treatments have all been found to increase the amount of time Parkinson's symptoms are well managed throughout the day. You can learn more about these and other emerging therapies by watching the entire May 2025 Live Well Today webinar recording. Watch the full webinar here: https://youtu.be/zqdXgoyVHT8 Medications discussed in this episode: Vyalev, the first 24-hour infusion of foslevodopa and foscarbidopa: https://davisphinneyfoundation.org/continuous-infusion-levodopa-approved-usa/ ONAPGO, an apomorphine infusion that offers rapid relief from OFF episodes: https://davisphinneyfoundation.org/continuous-infusion-apomorphine-approved/ And NeuroDerm ND0612, an investigational levodopa/carbidopa infusion, now in late-stage trials: https://neuroderm.com/our-solution/about/what-is-nd0612/ Season 6 Episode 9

The amazing duo of Sam Okun & Amir Ohebsion talk about the latest release “All There Is” as a dramatic examination of parent-child relationship & how the media shapes our society centering on a trouble teenager whose world is upended when a tragedy involving her best friend is blamed on her movie-star Dad's controversial sci-fi film and how the film explores mental health, suicide, death& the afterlife! Sam is a film producer/director of Sam Okun Productions specializing in developing a wide range of content from original screenplays to book adaptations including “Prisoner's Daughter”, “Anatomy of a Murder”, etc. Amir is an L.A. based-writer/producer/founder of  Soul Mining Productions including “The Apology”, “Jimmy Vestvood Amerikan Hero” etc. The movie stars Jason Priestly, Mena Suvari, Laurel Madsen, Elsie Fischer, Cheyenne Jackson and check out www.samokunproductions.com and www.soulminingproductions.com today! #samokun #amirohebsion #fildirector #filmproducer #allthereis #samokunprodcutions #soulminingproductions #parentchildrelationship #troubledteenager #prisonersdaughter #amnatomyofamurderer #theapology #jimmyvestvood #amerikanhero #jasonpriestly #menasuvari #laurelmadsen #elsiefischer #cheyennejackson #spreaker #iheartradio #spotify #applemusic #youtube #anchorfm #bitchute #rumble #mikewagner #themikewagnershow #mikewagnerallthereis #themikewagnershowallthereis #mikewagnersamokun #themikewagnershowsamokun #mikewagneramirohebsion #themikewagnershowamirohebsion

The amazing duo of Sam Okun & Amir Ohebsion talk about the latest release “All There Is” as a dramatic examination of parent-child relationship & how the media shapes our society centering on a trouble teenager whose world is upended when a tragedy involving her best friend is blamed on her movie-star Dad's controversial sci-fi film and how the film explores mental health, suicide, death& the afterlife! Sam is a film producer/director of Sam Okun Productions specializing in developing a wide range of content from original screenplays to book adaptations including “Prisoner's Daughter”, “Anatomy of a Murder”, etc. Amir is an L.A. based-writer/producer/founder of  Soul Mining Productions including “The Apology”, “Jimmy Vestvood Amerikan Hero” etc. The movie stars Jason Priestly, Mena Suvari, Laurel Madsen, Elsie Fischer, Cheyenne Jackson and check out www.samokunproductions.com and www.soulminingproductions.com today! #samokun #amirohebsion #fildirector #filmproducer #allthereis #samokunprodcutions #soulminingproductions #parentchildrelationship #troubledteenager #prisonersdaughter #amnatomyofamurderer #theapology #jimmyvestvood #amerikanhero #jasonpriestly #menasuvari #laurelmadsen #elsiefischer #cheyennejackson #spreaker #iheartradio #spotify #applemusic #youtube #anchorfm #bitchute #rumble #mikewagner #themikewagnershow #mikewagnerallthereis #themikewagnershowallthereis #mikewagnersamokun #themikewagnershowsamokun #mikewagneramirohebsion #themikewagnershowamirohebsion

The amazing duo of Sam Okun & Amir Ohebsion talk about the latest release “All There Is” as a dramatic examination of parent-child relationship & how the media shapes our society centering on a trouble teenager whose world is upended when a tragedy involving her best friend is blamed on her movie-star Dad's controversial sci-fi film and how the film explores mental health, suicide, death& the afterlife! Sam is a film producer/director of Sam Okun Productions specializing in developing a wide range of content from original screenplays to book adaptations including “Prisoner's Daughter”, “Anatomy of a Murder”, etc. Amir is an L.A. based-writer/producer/founder of  Soul Mining Productions including “The Apology”, “Jimmy Vestvood Amerikan Hero” etc. The movie stars Jason Priestly, Mena Suvari, Laurel Madsen, Elsie Fischer, Cheyenne Jackson and check out www.samokunproductions.com and www.soulminingproductions.com today! #samokun #amirohebsion #fildirector #filmproducer #allthereis #samokunprodcutions #soulminingproductions #parentchildrelationship #troubledteenager #prisonersdaughter #amnatomyofamurderer #theapology #jimmyvestvood #amerikanhero #jasonpriestly #menasuvari #laurelmadsen #elsiefischer #cheyennejackson #spreaker #iheartradio #spotify #applemusic #youtube #anchorfm #bitchute #rumble #mikewagner #themikewagnershow #mikewagnerallthereis #themikewagnershowallthereis #mikewagnersamokun #themikewagnershowsamokun #mikewagneramirohebsion #themikewagnershowamirohebsionBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-mike-wagner-show--3140147/support.

Episode 124  Like many visual effects artists of a certain vintage, Jeff Okun didn't plan on a career in VFX. In fact, by his own account, he didn't even plan to work in film at all. "I'm a completely accidental human being," he told me with a chuckle. His ambitions began on a very different stage — as a stand-up comic — until a sharply atheistic routine delivered at home earned him a lifetime ban from performing in front of his parents. Instead, Okun's creative outlet took the form of magic tricks, homemade stunts, and Super 8 visual gags. “I would blow up model ships and fake fights in rush hour traffic,” he said, “and I'd be in the bushes filming with ketchup for blood.” All of this childhood chicanery ultimately gave way to a fascination with the trickery of movies — the kind of illusions you could only pull off with careful camera work, sleight-of-hand editing, and an appetite for mischief. Learning the Craft the Hard Way Okun's first job in film was with the legendary graphic designer and filmmaker Saul Bass. The experience was, in Okun's words, “awful,” but also profoundly formative. As Bass's gopher-turned-editor, Okun was thrown into the deep end. “I hated him,” he laughed. “But he taught me everything: editing, sound, post-production supervision, how to shoot, how to frame. It was a masterclass.” Working for Bass meant operating in a visually precise, effects-heavy style — layering camera moves, creating in-camera effects, and often relying on labor-intensive optical printing processes. When optical houses turned down Bass's business — too exacting, too expensive — Okun stepped in with cost-saving workarounds and pricing schemes that actually worked. “We doubled the budget, added a contingency, and somehow still landed exactly on target.”“By the end of it, I ended up loving the man,” Okun said. “Not because he gave me a break, but because he was so specific and difficult to please that when you did please him, it meant something. He learned how to prep lineup sheets, how to composite with interpositives, and how to break down 140-layer optical shots into manageable components. “I was just the fix-it guy. I didn't know what I was doing half the time. I still don't.” VFX by Way of Accident It wasn't long before optical houses and producers began calling on Okun when their films were in trouble. One fix led to another. His reputation grew as someone who could step into a crisis and calmly solve it — usually with a combination of ingenuity, humour, and brute-force trial and error. “I think Saul trained me to see puzzles. That's what it comes down to — seeing what's broken and putting it together in a way that works. Most of the time, it wasn't about having the right answer. It was about trying 50 wrong ones.” This kind of lateral thinking came into its own on films like Stargate (1994), where Okun — working with Jeff Kleiser and Diana Walczak's fledgling CG company — had to convince director Roland Emmerich that computer graphics were even worth attempting. “Roland didn't believe in CG. So we built the shot, made the CG glider deliberately less detailed to match the miniature footage. Showed it to him. He said, ‘Exactly — that's what I'm talking about. Miniatures are the way to go.' And we said, ‘Nope. All CG.' That's when he finally came around.” (Fun fact, VFX supervisor Jeff Okun was paid homage by Brent Spiner in Independence Day in the role of Dr. Brackish Okun. There's uh, a slight resemblance.) - Credit to Nofilmschool.comPenguins, Moose, and the Invisible Effect Okun is quick to point out he wasn't a Star Wars kid. In fact, he avoided the original film for weeks on principle — he doesn't do queues. But he did get a behind-the-scenes tour of ILM's original Van Nuys facility courtesy of Bass and George Lucas. There, he saw motion control rigs, Richard Edlund on his knees filming the crawl, Phil Tippett animating the chess game, and pyro tests in the parking lot. It was, he admits, a little magical — though it didn't change the fact that his creative allegiance remained with illusion, not spectacle. “My favourite effects are the invisible ones. I started out as a magician. The goal is to make people believe there's no trick. That's where the real artistry is.” Still, that didn't stop him from sneaking penguins and moose into the background of multiple films. He once gave a horse antlers in a Cameron Crowe movie. In Blood Diamond, he added a huge penguin family to a wide evacuation shot — no one noticed. “It's like the gorilla basketball video. You just don't see what you're not looking for.” The Shark That Ate Sam Perhaps his most famous — or infamous — contribution to pop culture came on Deep Blue Sea. Samuel L. Jackson had just delivered a particularly rough eight-page monologue, and Okun, unimpressed with the script, asked Jackson what he wanted to do. “He just said, ‘Kill me.' So I said, ‘If you make it to the front of the moon pool, I'll kill you.'” The surprise shark attack that interrupts Jackson mid-speech is now legendary. It wasn't in the script. “Renny Harlin didn't know until the day,” Okun said. “Sam did take after take but always got to the kill spot early. We cut the rest. I shot the elements. It was a massacre. We even had baby sharks pull him apart for fun.” The Changing Landscape Much of our conversation revolved around the changing realities of visual effects — the rise of AI, the complications of LED walls, and the shifting expectations from directors and studios. “People think VFX is just hitting the ‘do it right' button and then the ‘do it fast' button,” he said. “There's so little appreciation for how hard this stuff is, and we've done ourselves no favours by making it all invisible.” He sees today's VFX artists as increasingly anonymous — a shift he's spent much of his career trying to reverse, both through his own visibility and via his tenure at the Visual Effects Society. “We don't sell our artistry. We sell our software. You know the names of the DPs, but no one can name last year's VFX Oscar winners. That's not sustainable.” The Invisible War Stories At the end of our chat, Okun expressed a desire to tell more of the “true” stories of VFX — the screw-ups, the late-night fixes, the shots that weren't supposed to work. He wants more people to know that the chaos behind the curtain is often where the real creative breakthroughs happen. “It's always fun. That's the only reason I still do it. And when it's collaborative, when it's people bouncing ideas off each other, it's magical. That's when everyone forgets the pain and just remembers the movie.”All the Filmumentaries Links

Quote of The Day: “Stop Pre-Rejecting yourself and calling it humility.” - Wade Joye Hosts: TOLA Omoniyi. Kanyinsola Omojola

It's time to discuss reciprocal tariff day - and all the uncertainty that comes with it - with Steve Okun, CEO, APAC Advisors. He also tackles the impact of climate change on Singapore businesses and the culture war against… Snow White! "Saturday Mornings Show" host Neil Humphreys joins Steve as they try to make some sense of another chaotic week.See omnystudio.com/listener for privacy information.

The stealthy US Ambassador-designate to Singapore has the diplomatic world wondering who he is. Eight Senate Democrats join with Republicans to pass a Continuing Resolution to fund the government, and US "hunting influencer" bolts Australia and blames everyone else for her on-camera stunt to snatch a baby wombat from its mother. We discuss it all with Steve Okun, CEO APAC Advisors during the International News Review, with "Saturday Mornings Show" host Glenn van Zutphen and co-host Neil Humphreys.See omnystudio.com/listener for privacy information.

We focus on a confusing week of US tariffs and push-back from trading partners with Steve Okun, CEO, APAC Advisors and Deborah Elms, Head of Trade Policy, Hinrich Foundation. What's President Trump's plan and end-game? How might his current posture impact companies in Singapore and across Asia. "Saturday Mornings Show" host Glenn van Zutphen and co-host Neil Humphreys try to make some sense of it all.See omnystudio.com/listener for privacy information.

Send us a textIn his book The Squad, journalist Ryan Grim provides an account of the experiences of “The Squad,” a group of progressive legislators elected to the House of Representatives, as they attempted to govern. Their journey—from election victories to struggles with Republicans and Democratic leadership—is widely praised for its detailed investigation of the electoral and political “inside baseball” of the left. Grim's role as a critical figure in independent left media, through appearances on shows like Breaking Points and his publication Drop Site, further enhances the book's value as a vantage point for those interested in evaluating the rising establishment “Left” as a tool for advancing the interests of Black people and the Black community. It helps readers take stock of where the Left stands, where it might be going, and whether it can serve as a vehicle for achieving the Black community's goals.In conversation with Leaders of a Beautiful Struggle Director of Research Lawrence Grandpre, LBS Director of Public Policy Dayvon Love examines The Squad to uncover critical insights about both the Left and media analysis. Love highlights how the book reveals that, despite high-profile victories over Democratic Party establishment figures, the political Left suffers from a stunning lack of infrastructure. He links this to the Left's general failure to prioritize building political machinery and institutions. Grim's analysis of the Left's frustration with concepts like Tema Okun's “white supremacy culture” reflects the frustrations of grassroots advocates, who have seen anti-racism abstracts used by some to center conversations on personal feelings rather than delivering political outcomes for the communities they claim to serve.However, Love also critiques Grim's analysis, particularly his dismissal of cultural frameworks. In addressing Okun's “white supremacy culture,” Grim, like many on the Left, overcorrects by rejecting tools like African-centered analysis for political work. This is evident in his dismissal of Leonard Jeffries, the uncle of House Minority Leader Hakeem Jeffries, whom Grim labels an “antisemite.” This overlooks valid concerns Black community advocates have raised about white advocates monopolizing resources intended for the Black community under the guise of representing their interests. By dismissing such critiques as “antisemitism,” Grim ironically mirrors the tactics he criticizes liberals for using—employing blanket accusations to sideline political conversations that challenge entrenched interests.Support the showIn Search of Black Power is a Black-owned internet show and podcast. This podcast is sponsored and produced by Leaders of a Beautiful Struggle (LBS). The internet show is published in collaboration with Black Liberation Media (BLM)

Lv.143配信です。 //// つきいちさんの制作物 /////////////// 下記のリンクからご覧いただけます。 演劇企画カタアシイッポ第三回本公演『アルクビエレ』 ■脚本こちら https://drive.google.com/file/d/11HP-RWDRj52JoG2ZZ2HS0UblgJYMwWNX ■当日の様子はこちら(本編7:30から ) https://youtu.be/D341k9eflvI?si=TjCeJjGpFGKWuSBz ※※転載･無断使用は御遠慮ください※※ //// 出演 /////////////// こへい ゲスト：okunさん／つきいちさん //// キーワード /////////////// ゲストはゲームすっきゃねんokunさん＆つきいちさん／OuterWilds //// チャプター /////////////// (00:00)｜OP「ゲストはokunさん＆つきいちさん」 (18:43)｜本編「OuterWilds負け組の会をなんとか」 (01:22:03)｜ED //// 番組へのおたより /////////////// 番組へのおたより・メッセージは番組ウェブサイト（ https://gamenantoka.com/ ）または gamenantoka@gmail.com へお送りください。 //// 番組YouTubeチャンネル /////////////// ゲームなんとかの今後の活動の幅を広げるため、さらなる番組リスナーさん増加を目指してYouTubeチャンネルを開設しました。ポッドキャストと同じ音源を配信だけではなく、動画ならではの取り組みも挑戦していこうかと思いますので、ぜひともチャンネル登録をお願いいたします。https://www.youtube.com/c/gamenantoka //// その他 /////////////// ■ハッシュタグ 番組の感想やリスナーさん同士の交流には #ゲームなんとか をお気軽にお使いください！ ■番組twitter：@gamenantoka

How are you really sleeping these days? Be honest—are you waking up feeling refreshed, or is it more like dragging yourself out of bed and powering through the day on fumes? If that sounds familiar, you're not alone. Sleep is a huge part of feeling like your best self, but it's so easy to overlook. In this podcast episode, I'm sitting down with my friend, Dr. Michelle Okun, a health psychologist and sleep scientist. We're talking about how sleep impacts literally everything—your mood, your stress levels, your health, and even your energy. We're diving into the science of why sleep matters and the simple things you can do to feel like your best self again. Don't worry, your sleep helpline is here!  So, grab a cup of tea, cozy up, and let's talk about how to get the rest you need to feel amazing. You deserve this!

Will the Gaza Ceasefire hold? Can Biden rescue his Presidential legacy? Trump goes indoors for his inauguration. Finally a good slice in Singapore. During our International News Review, Saturday Mornings Show host Glenn van Zutphen and co-host, Neil Humphreys we cover these topics and more with Steve Okun, CEO APAC Advisors.See omnystudio.com/listener for privacy information.

In this episode, Brain & Life Podcast co-hosts Dr. Daniel Correa and Dr. Katy Peters answer some listener-submitted questions. Then, Dr. Correa is then joined by Dr. Michael Okun, co-director of the Center for Movement Disorders and Neurorestoration, and the Adelaide Lackner Professor of Neurology at the University of Florida. Dr. Okun sheds light on the increasing rates of Parkinson's disease diagnosis in our communities, environmental factors that may contribute to the disease, and important considerations for those diagnosed with Parkinson's.   Additional Resources Parkinson Secrets Skin Problems May Be Early Signs of a Neurologic Condition Factors That May Increase the Risk of Parkinson's Disease Parkinson's Disease Won't Extinguish This Firefighter's Passion   Other Brain & Life Podcast Episodes Ed Begley Jr. on Utilizing a Healthy Lifestyle to Thrive with Parkinson's Disease How American Ninja Warrior Jimmy Choi Rose Above Parkinson's Comedy and Courage: Comedian Richard Lewis on Living with Parkinson's Disease   We want to hear from you! Have a question or want to hear a topic featured on the Brain & Life Podcast? ·       Record a voicemail at 612-928-6206 ·       Email us at BLpodcast@brainandlife.org   Social Media:  Dr. Michael Okun @michaelokun @fixelinstitute Hosts: Dr. Daniel Correa @neurodrcorrea; Dr. Katy Peters @KatyPetersMDPhD

On the International News Review: Steve Okun & Peter Goelz join Saturday Mornings Host Glenn van Zutphen and co-host Neil Humphreys to discuss Biden's Sinking the Steel Deal, Carter from the inside, and Global Airline Turbulence.See omnystudio.com/listener for privacy information.

During our International News Review, Saturday Mornings Show host Glenn van Zutphen and co-host, author Neil Humphreys speak to Steve Okun, CEO APAC Advisors about: ○ Why Trump invited Xi to his January 2025 inauguration and why Xi gave a hard no. ○ Who are your top 3 most influential people of 2024? We tell you ours. ○And what were the 10 most popular internet searches of 2024 among Singaporeans?See omnystudio.com/listener for privacy information.

The International News Review on "Saturday Mornings" with Glenn van Zutphen and co-host Neil Humphreys with APAC Advisors CEO Steve Okun. Why is Elon Musk dissing Singapore? Malaysia just says “no” to China as a trade transit hub. The China-US trade war is well underway with recent announcements. And, Singapore's Civil Service is on top of the global rankings! #SaturdayMornings #News #InternationalNews #Geopolitics #Singapore #GlobalAffairs #civilservice See omnystudio.com/listener for privacy information.

Understand the impact of the US elections on Singapore and Southeast Asia Join "Saturday Mornings" host Glenn van Zutphen and co-host Neil Humphreys for their International News Review US Election Special. APCA Advisors CEO Steve Okun and Angela Mancini, Partner at Control Risks break down the election results and analyze their implications in the US, for Singapore, and business across the region.

Listen to Saturday Mornings host "Glenn van Zutphen and co-host Neil Humphreys" as they talk with Steve Okun, CEO of APAC Advisors about the potential impact of the upcoming US election on Singapore and the surrounding region. What might it mean for trade and security? This insightful episode explores the international news of the week and examines the final days of the US presidential campaigns.See omnystudio.com/listener for privacy information.

Join MoneyFm89.3 hosts Glenn van Zutphen and Neil Humphreys on the "Saturday Mornings Show" for their weekly International News Review with Steve Okun, Senior Advisor at McLarty Associates. This week they discuss: *   The US election and the final stages of the campaigns. *   Singapore's new framework designed to hold telcos and financial institutions accountable for scam victims. *   King Charles' recent encounter with an anti-monarchist heckler during his visit to Australia.  *   What are the destinations that fresh grads most want to move to for work?See omnystudio.com/listener for privacy information.

During our International News Review, Saturday Mornings Show host Neil Humphreys and Steve Okun discuss the impact of global security risks on the Singapore economy, false advertising among fossil fuel firms and Eduardo Saverin's contribution to the Singapore American School..See omnystudio.com/listener for privacy information.

The 2024 President's Cup kicks off in Montreal, where the American's turn a new page without familiar faces on the team, but with the world's best as they look to extend their unbeaten streak since 1998.LIV Golf wrapped up their season in Dallas with the Team Championship, and Cam Smith's Ripper GC took the grand prize.The BMW PGA Championship in Surrey, England ended in heartbreak for Rory McIlroy, who Michael says will never win a big championship ever again.On the LPGA Tour, Lydia Ko continued her late season dominance with another win, making a case for golfer of the year.In Tuned In, Alex is enjoying a new comedy on on Hulu with a surprisingly unfunny name.This week's guest is Kelly Okun, a former professional golfer turned content creator, podcaster, and now Founder and CEO of Fairway to Green, a media company focused on equality and women's sports. Kelly returns to the pod to chat about her new venture, plus what it was like at the Pairs Olympics and Solehim Cup this year.The WNBA is now in the postseason, and while we all may be rooting for Caitlin Clark, it doesn't look good for the Fever to get past the Connecticut Sun.Football season rolls on as Texas holds on to the top college spot. Alex's Baby Bets continue to hit, but Michael's NY Giants just happens get lucky sometimes.Baseball enters the final week of the season that has included some of the best baseball ever seen (Shohei Ohtani) and some of the worst (the Chicago White Sox).As the guys #AlwaysEndWithFood, Alex shares an update on being a griddle man, while Michael does a live taste test of Coke Zero Sugar Oreo. Support our friends!Save 10% on a Phone Caddy, Swing Aide Tumbler, and everything else with promo code COURSEOFLIFE at DesertFoxGolf.comUse our special link - https://zen.ai/thecourseoflife - to save 30% off your first month of any Zencastr paid plan. Listen + Love + Subscribe: https://podfollow.com/1437411449Support the First Tee - Greater Austin: https://bit.ly/3n09U4IJoin us on Facebook: http://bit.ly/2NpEIKJFollow us on Instagram: https://bit.ly/2QJhZLQWatch us on YouTube: http://bit.ly/3qvq4Dt

During our International News Review, Saturday Mornings Show host Neil Humphreys and Steve Okun discuss the shocking walkie-talkie and pager blasts in Lebanon, Republicans turning their backs on Donald Trump and a U-turn in orangutan diplomacy.See omnystudio.com/listener for privacy information.

During our International News Review, Saturday Mornings Show host Glenn van Zutphen and co-host, author Neil Humphreys speak to Steve Okun, Senior Advisor, Mclarty Associates about the Typhoon Yagi massive flooding with over 200 deaths in Vietnam, the UK PM Starmer says Russia's Ukraine war can end “straight away”, Will the US Presidential debate matter for Kamala Harris or Donald Trump and North Korea shows its nuclear laboratory.See omnystudio.com/listener for privacy information.

In this episode of the podcast, we catch up with Kelly Okun. Kelly is a second year student in UVA Darden's Full-Time MBA Class of 2025, and she is also a founder. We talk with Kelly about her decision to pursue an MBA, what led her to Darden, her experience in Darden's iLab summer incubator, her advice for prospective students and more. Kelly's venture, Fairway to Green, covers all areas of golf and seeks to increase the visibility and funding for the women's game. For more insights, tips, and stories about the Darden experience, be sure to check out the Discover Darden Admissions blog and follow us on Instagram @dardenmba.

Sam Okun Productions is a film and television development and financing company specializing in the discovery and production of forward thinking content with broad international and multi-generational appeal. In collaboration with other leading production companies, financiers, and film studios, Sam Okun and his team consistently strive to push boundaries with modern adaptations of classic novels by some of the most world renowned best selling authors while also working with young, up and coming authors to bring their visions to the screen. In addition to adaptations, Sam Okun Productions develops original content of all genres with a particular interest in cross-genre works. Sam Okun Productions is committed to innovation, and is heavily involved in pursuing adaptations of video-games and other forms of new media.

From 18th century London to the promise of a global cure: the 200-year history of Parkinson's disease. Parkinson's, a neurodegenerative disorder most commonly characterized by tremors and other motor symptoms, is so complex, many medical professionals are starting to classify it as a group of diseases, rather than a single disease. In this episode, we explain those complexities, including: • The motor symptoms (e.g. cogwheel rigidity, bradykinesia) and non-motor symptoms (e.g. depression, sleep disorders) • How the industrial revolution may have brought about environmental factors which contribute to Parkinson's • The differences and similarities between Parkinson's and other neurodegenerative diseases, like Alzheimer's • How Parkinson's manifests in our brains • Why one nurse was able to detect Parkinson's through smell • The neurogenetics of Parkinson's, and the ethical quandaries of evolving genetic technology • Why lifestyle — nutrition, exercise, etc. — is so key to preventing and managing Parkinson's Joining us for this extensive conversation are three incredible guests: • Dr. Rachel Dolhun, Senior Vice President of Medical Communications at The Michael J. Fox Foundation for Parkinson's Research • Dr. Michael Okun, evolutionary biologist, movement disorders specialist, and Director of the Norman Fixel Institute for Neurological Diseases • Dr. Matthew Farrer, neurogenetics expert and Professor Of Neurology at the University of Florida ‘Your Brain On' is hosted by neurologists, scientists and public health advocates Ayesha and Dean Sherzai. Drs. Ayesha and Dean are now welcoming patients via the Brain Health Institute: https://brainhealthinstitute.com/ ‘Your Brain On... Parkinson's' • SEASON 3 • EPISODE 1 (SEASON 3 DEBUT) ————— LINKS   Dr. Rachel Dolhun: At the Michael J. Fox Foundation: https://www.michaeljfox.org/bio/rachel-dolhun-md-dipablm  ‘Ask the MD' series: https://www.michaeljfox.org/ask-md  The Michael J. Fox Foundation on YouTube: https://www.youtube.com/@michaeljfoxfoundation/videos  Dr. Michael Okun: At the University of Florida: https://neurology.ufl.edu/profile/okun-michael/  The book ‘Ending Parkinson's Disease': https://endingpd.org/  The Norman Fixel Institute: https://fixel.ufhealth.org/   Dr. Matthew Farrer: At the University of Florida: https://neurology.ufl.edu/profile/farrer-matthew/ ————— References: Bloem, B. R., Okun, M. S., & Klein, C. (2021). Parkinson's disease. The Lancet, 397(10291), 2284-2303. Morris, H. R., Spillantini, M. G., Sue, C. M., & Williams-Gray, C. H. (2024). The pathogenesis of Parkinson's disease. The Lancet, 403(10423), 293-304. Dorsey, E., Sherer, T., Okun, M. S., & Bloem, B. R. (2018). The emerging evidence of the Parkinson pandemic. Journal of Parkinson's disease, 8(s1), S3-S8. Dorsey, E. R., Okun, M. S., & Tanner, C. M. (2021). Bad Air and Parkinson Disease—The Fog May Be Lifting. JAMA neurology, 78(7), 793-795. Tsalenchuk, M., Gentleman, S. M., & Marzi, S. J. (2023). Linking environmental risk factors with epigenetic mechanisms in Parkinson's disease. npj Parkinson's Disease, 9(1), 123. Reynoso, A., Torricelli, R., Jacobs, B. M., Shi, J., Aslibekyan, S., Norcliffe‐Kaufmann, L., ... & Heilbron, K. (2024). Gene–Environment Interactions for Parkinson's Disease. Annals of Neurology, 95(4), 677-687. Golsorkhi, M., Sherzai, A., & Dashtipour, K. The Influence of Lifestyle on Parkinson's Disease Management. In Lifestyle Medicine, Fourth Edition (pp. 919-924). CRC Press. Sherzai, A. Z., Tagliati, M., Park, K., Pezeshkian, S., & Sherzai, D. (2016). Micronutrients and risk of Parkinson's disease: a systematic review. Gerontology and geriatric medicine, 2, 2333721416644286. ————— FOLLOW US  Join the NEURO Academy: NEUROacademy.com  Instagram: @thebraindocs Website: TheBrainDocs.com More info and episodes: TheBrainDocs.com/Podcast

Chuck and Roxy are back and open the show with a few emails and a quick recap of “Bachelorette,” "Friends" and are now looking for their next “rewatch” / “first watch!” Next it's time to "Meet the Littles" as our hosts welcome Steve Okun to the podcast. We get all into how he spent time with the Clinton campaign back in the 90's. (19:30) LINKEDIN: SEARCH Steven Okun Then our hosts close out the show with your emails and notes. (46:00) SONG: "Fallen From My Tree" by Lorenza Wildcard INSTAGRAM & TWITTER: @lorenzawildcard EMAIL: lorenzawilcard@gmail.com JINGLE: Gummi Bears Theme (ALBANESE REMIX) A parody of a song by Joseph Williams. A Collaboration by ELLIOT OLSHANSKY & Jerry Negrelli Recorded: 06/03/2022  Released: 06/03/2022  First aired: 06/29/2022 Podcast Website - www.loyallittlespod.com  Podcast Email - WTFCPODNET@GMAIL.COM Twitter:@loyallittlespod Instagram: @theloyallittlespodcast PODCAST LOGO DESIGN by Eric Londergan www.redbubble.com Search: ericlondergan or copy and paste this link! https://www.redbubble.com/people/ericlondergan/shop --- Support this podcast: https://podcasters.spotify.com/pod/show/loyallittles/support

"Dr. Amy Okun is a general dentist and owner of Okun Dentistry (www.okundentistry.com)and Sandstrom Dental Group (www.drsandstrom.com) in Arizona.  Dr. Okun found her passion early on, choosing to embrace her family legacy in dentistry for its flexibility and entrepreneurial opportunities. Her “boss mom” example had a profound impact on her entrepreneurial son Dylan, starting his first business venture at age 11. After 20 years of running her private practice, she partnered with MB2 Dental in 2022 to leverage their systems and support while breathing new life and “Okunizing” existing practices, like her recent second location. Dr. Okun is a cheerleader for MB2 Dental as a partner that allows her to focus on her patients and her passion for innovation. " ------------------------------------------- Subscribe & Listen: Spotify: https://open.spotify.com/show/69Dz26hgC9D6YqwN8JMDBV?si=f4c86e301ef247aa Apple Podcast: https://podcasts.apple.com/us/podcast/mb2-underground/id1747349567 ------------------------------------------------ Follow MB2 Dental on Social: MB2 Dental: https://www.mb2dental.com Instagram: https://www.instagram.com/mb2dental/ Facebook: https://www.facebook.com/mb2dental YouTube: https://www.youtube.com/channel/UCm9GvCRXwQTMBb61cf16r0Q LinkedIn: https://www.linkedin.com/company/mb2-dental/ 

Unlock the secrets of securing capital for your startup as I, Michael Gayed, join forces with NYU Stern's own Professor Glenn Okun to unravel the complexities of entrepreneurial finance in today's challenging economy. Together, we dissect the current climate where surging interest rates are reshaping the terrain for rising businesses, scrutinizing the high barriers and intensified competition for investment. This episode is a treasure trove for entrepreneurs looking to navigate the stormy seas of venture capital and establish a stronghold in a market where Goliaths are increasingly dominant.Venture beyond the startup scene with us as we also tackle the thorny issues around the green energy transition and the fallout from COVID-induced financial landscapes. Diving into the world of investment strategies, we question the viability of passive approaches in an age of market anomalies and scrutinize the energy sector's pivot toward practices that favor shareholders. With Professor Okun's expertise lighting the path, we examine the forces of political sway, corporate power plays, and technological breakthroughs that could very well overturn the status quo of the investment universe. Tune in for an episode that promises to equip you with the insights to make savvy decisions in a market brimming with both peril and promise.The content in this program is for informational purposes only. You should not construe any information or other material as investment, financial, tax, or other advice. The views expressed by the participants are solely their own. A participant may have taken or recommended any investment position discussed, but may close such position or alter its recommendation at any time without notice. Nothing contained in this program constitutes a solicitation, recommendation, endorsement, or offer to buy or sell any securities or other financial instruments in any jurisdiction. Please consult your own investment or financial advisor for advice related to all investment decisions. Sign up to The Lead-Lag Report on Substack and get 30% off the annual subscription today by visiting http://theleadlag.report/leadlaglive. Foodies unite…with HowUdish!It's social media with a secret sauce: FOOD! The world's first network for food enthusiasts. HowUdish connects foodies across the world!Share kitchen tips and recipe hacks. Discover hidden gem food joints and street food. Find foodies like you, connect, chat and organize meet-ups!HowUdish makes it simple to connect through food anywhere in the world.So, how do YOU dish? Download HowUdish on the Apple App Store today:

In our International News Review, Saturday Mornings host Neil Humphreys and co-host Dan Koh speak to Steven Okun, Senior Advisor, McLarty Associates about Blinken's pledge to back the Philippines in China, Singapore's commitment to Gaza and Malaysia seeing red over Deep PurpleSee omnystudio.com/listener for privacy information.

In our International News Review, Saturday Mornings host Glenn van Zutphen and co-host, award-winning author Neil Humphreys speak to Steve Okun, Senior Advisor, Mclarty Associates about Putin's election weekend and his threat to use nukes if Russia's sovereignty is threatened, The US Congress moves closer to banning Tik Tok, Biden and Trump win Primaries, the highest ranking Jewish Democrat in Congress calls for elections to replace Israel's Netanyahu, and how will Singapore respond to the 2024 election result?See omnystudio.com/listener for privacy information.

In our International News Review, Saturday Mornings host Glenn van Zutphen and co-host, award-winning author Neil Humphreys speak to Steve Okun, Senior Advisor, Mclarty Associates about Singapore's goes for the gold with its Taylor Swift concert strategy. Regional HQs are choosing SG over HK. The severity of climate change is threatening India's workers and economy, and Jack Ma's wife Zhang Ying goes shophouse shopping in Duxton Hill.See omnystudio.com/listener for privacy information.

In our International News Review, Saturday Mornings host Glenn van Zutphen and co-host, award-winning author Neil Humphreys speak to Steve Okun, Senior Advisor, Mclarty Associates about the Taiwan national elections, the impact of US-British strikes against Houthi targets in Yemen, Boeing trying to figure out where it has a screw loose, the US Presidential primaries heat up, and Mark Zuckerberg's plan to make more moo-lah with macadamia nuts and beer.See omnystudio.com/listener for privacy information.

In our International News Review, Saturday Mornings host Glenn van Zutphen and co-host, award-winning author Neil Humphreys speak to Steve Okun, Senior Advisor, Mclarty Associates about the decades-long air safety improvement that likely saved lives on the JAL air crash in Japan, why the Israeli post-war Gaza plan is controversial, the issues around India's Bollywood writers strike, and the US lawsuit around faceless chocolate.See omnystudio.com/listener for privacy information.

I invited educator, writer, artist and activist Tema Okun (she/her) to talk with us about holiday traditions, rituals, and cultural appropriation. What she offered was deep wisdom from her personal life and decades of work as a DEI facilitator, author and professor. I hope this episode prompts reflection and provides encouragement to keep healing and growing. Tema Okun has spent over 35 years working with and for organizations, schools, and community-based institutions as a trainer, facilitator, teacher, and mentor focused on issues of racial justice and equity. She got her start at Grassroots Leadership. For 12 years she worked with the late and beloved Kenneth Jones at ChangeWork and then for another decade with Michelle Johnson and many brilliant colleagues at Dismantling Racism Works. She recently completed 6 years of co-leading the Teaching for Equity Fellows Program at Duke University, which works with faculty seeking to develop stronger skills both teaching about race and racism and across lines of race, class, and gender. She also facilitates and support leaders and organizations with colleagues at Teach.Equity.Now., housed at the Pauli Murray Center in Durham, NC. She was a member of the Educational Leadership faculty at National Louis University in Chicago and has taught undergraduate, master's, and doctoral level students in educational leadership and education. She is the author of the award-winning The Emperor Has No Clothes: Teaching About Race and Racism to People Who Don't Want to Know (2010, IAP) and the widely used article White Supremacy Culture, which she is asking people to stop using and instead reference a website based on a revision and update of the article in May 2021: www.whitesupremacyculture.info. She publishes regularly on the pedagogy of racial and social justice. She is a member of the Bhumisphara Sangha under the leadership of Lama Rod Owens and a participant in The Infinite Circle at Breadloaf Mountain Zen Center. She is an artist, a poet, and a writer. She lives in Carrboro, NC where she is fortunate to reside among beloved community. Her current project is deepening her ability to love her neighbor as herself. She is finding the instruction easy and the follow through challenging, given how we live in a culture that is afraid to help us do either or both. RESOURCES Design Your Year Workshop Read: Divorcing White Supremacy Culture: Coming Home to Who We Really Are Dismantling Racism: A History Lesson White by Law: The Legal Construction of Race by Ian Haney Lopez Podcasts: Ruby Sales on the On Being podcast Tema Okun and Michelle Cassandra Johnson on All the F*ck In Organizations for education, community and action: Better Neighbor Lab We Are Finding Freedom The People's Institute for Survival and Beyond White Awake

"It's so important to have that outlook of everyone is human, everyone is worthy, but I also think it's important, for me, and for everyone to protect ourselves. [As a sensitive child growing up] to protect myself, I dove into movies, I dove into playwriting when I couldn't get that connection from anywhere else. The Arts is what saved me." Stephanie Okun is a playwright/screenwriter/director. She is a recent graduate of Wesleyan University, student at NYU's Educational Theatre MA program, and proud former intern/current member of New York Women in Film & Television (NYWIFT). At a young age, she discovered her love for playwriting and pursued it at Stephen Sondheim's Young Playwrights Inc., an organization that changed her life. For her, theater is home and she's always thrilled to be there.

In this brief episode, Kaitlyn Allen talks with Steven Okun, Founder and CEO of APAC Advisors. Steven has over 25 years of experience across government, public affairs, and communication.  Steven has lived and worked in Asia since 2003, serving as the Senior Advisor in ASEAN for EMPEA, formerly the Emerging Markets Private Equity Association, and is a member of their global ESG and impact working groups. He also created and led public affairs for KKR Asia Pacific from 2011-2017, including implementing their regional ESG policy. Listen as Kaitlyn and Steven announce ClimeCo's expansion in Singapore, and check out the official press release to learn more. In addition, Steven discusses three ESG focal points for the region: 1) addressing the climate crisis, 2) tackling human rights and supply chain concerns, and 3) addressing the surge in cyber security threats and ransomware attacks. These issues resonate with key stakeholders, including investors, corporate leaders, employees, and customers. Steven briefly addresses the transition to a low carbon economy, particularly the investor impact, with Singapore's carbon tax set to increase 5x next year. Unlock the world of sustainability and join the ESG Decoded Podcast community! Make sure to subscribe to be notified of new episodes on your favorite streaming platforms, YouTube, and our social channels (linked below). Get ready for thrilling new episodes that will ignite your passion for positive change. Tune in, engage, and let's decode ESG together! Episode Resource Links Steven's LinkedIn: https://www.linkedin.com/in/stevenokun/ Kaitlyn's LinkedIn: https://www.linkedin.com/in/kaitlyn-allen-sustainability/ APAC Advisors' Website: https://www.apacadvisors.com/about  ClimeCo's Expansion in Singapore: https://climeco.com/climeco-expands-presence-in-singapore-with-the-hire-of-anna-stablum/ 

The Stuph File Program Featuring Arlene Okun, founder & operator, The Sock Monkey Museum; Nick Witherill, CEO & founder, Binho Board; & Stuart Nulman with Book Banter Download Arlene Okun is the founder & operator of The Sock Monkey Museum. She has a Guinness World Record with over 2,100 of the plush pals. Nick Witherill is the CEO & founder of the very popular tabletop soccer game called Binho Board. Stuart Nulman with another edition of Book Banter. This week's reviewed title is Still Laughing: A Life in Comedy by George Schlatter (Unnamed Press/Rare Bird, $28). You can also read Stuart's reviews in The Montreal Times.  Now you can listen to selected items from The Stuph File Program on the new audio service, Audea. A great way to keep up with many of the interviews from the show and take a trip down memory lane to when this show began back in 2009, with over 800 selections to choose from! This week's guest slate is presented by M. J. Preston, author of the thriller novel, Four, the sequel to Highwayman. (He was a guest back February 2020 on show #0550).

In this episode, Dr. Soania Mathur interviews Dr. Michael Okun to discuss the latest therapies for Parkinson's, including RT-QUIC (Parkinson's biomarker), subcutaneous dopamine pumps, vibrating gloves, rescue medications, DBS, and more.  Dr. Mathur and Dr. Okun discuss: New discoveries in diagnosing Parkinson's What do certain biological markers mean for diagnosis? What's new on the horizon for Parkinson's treatments? The subcutaneous delivery of dopamine replacement Transdermal treatment Microbiome in Parkinson's Vibration therapy The importance of individualized care plans How to sort through all the information about Parkinson's and more. We hope you enjoy!

Caravans are making their way to the border to invade the second Title 42 expires. John from New York calls in to provide updates on the Consumer Price Index and Okun's Misery Index. All this plus the Chump Line? The King of New England Talk Radio is SO back.

“White Supremacy Culture,” an article by Tema Okun, was first written to outline and analyze how white supremacy operates in organizations. But in the past few years, with renewed attention on the racial justice movement, the short article has been used as a weapon within progressive organizations and by the right. As organizational infighting continues, many have used the article as a way to claim that basic elements of organizational life — editing, performance reviews, deadlines, urgency, the written word, perfectionism, etc. — are actually all characteristics of white supremacy culture. This week on Deconstructed, Tema Okun joins host Ryan Grim to discuss her article, its evolution, and its misuse, speaking out for the first time against its weaponization. Okun breaks down the history of her article, how it has been used in ways she did not intend, and what the true intention of the piece is. join.theintercept.com/donate/now Hosted on Acast. See acast.com/privacy for more information.